Practical study on the application of “BRAND”pharmaceutical care model in advanced NSCLC patients with positive driver genes
- VernacularTitle:“BRAND”药学服务模式用于驱动基因阳性晚期NSCLC患者的实践研究
- Author:
Jiankang YU
1
;
Wei GONG
1
;
Jinfang SHI
1
;
Jie TANG
1
;
Yinhua GONG
1
Author Information
1. Dept. of Pharmacy，the First Affiliated Hospital of Soochow University，Jiangsu Suzhou 215000，China
- Publication Type:Journal Article
- Keywords:
“BRAND” pharmaceutical care model;
positive driver gene;
advanced stage;
non-small cell lung cancer
- From:
China Pharmacy
2026;37(5):655-659
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE To establish a “BRAND” pharmaceutical care model for advanced non-small cell lung cancer （NSCLC） patients with positive driver genes， providing theoretical and practical references for the clinical implementation of precise and individualized oncology pharmaceutical care. METHODS One hundred patients admitted to the department of pulmonary and critical care medicine in our hospital from January 2023 to May 2024 were collected meeting the inclusion and exclusion criteria. Patients were randomly divided into control group and intervention group， with 50 patients in each group. The control group received routine pharmaceutical care， while the intervention group received pharmaceutical care under the “BRAND” model （collecting patients’ basic information， reviewing disease treatment-related information， conducting precise medication assessments， formulating individualized pharmaceutical care plans for the next steps， and implementing medication guidance and follow-up management）. The study was conducted in a 3-week cycle for a total of 4 cycles. The medication compliance， quality of life， laboratory test indicators， incidence of drug-related adverse events and satisfaction of patients in both groups were compared before and after the intervention to evaluate the effects. RESULTS After 12 weeks of intervention， compared with the control group， the medication compliance， cognitive function， social function and satisfaction of patients in the intervention group were improved significantly （ P ＜0.05）； the severity of fatigue and constipation and the incidence of drug-related adverse events were significantly reduced （ P ＜0.05）， and there was no statistically significant difference in laboratory test indicators （ P ＞0.05）. CONCLUSIONS The “BRAND” pharmaceutical care model can effectively improve the medication compliance of patients with advanced NSCLC with positive driver genes and improve their quality of life. This study can provide a feasible path for clinical pharmacists to carry out standardized and high-quality pharmaceutical care.
